The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition

BACKGROUND: Combined targeting of MAPK and PI3K signalling pathways may be necessary for optimal therapeutic activity in cancer. This study evaluated the MEK inhibitors AZD6244 and PD0325901, alone and in combination with the dual mTOR/PI3K inhibitor NVP-BEZ235 or the PI3K inhibitor GDC-0941, in thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Haagensen, E J, Kyle, S, Beale, G S, Maxwell, R J, Newell, D R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326670/
https://www.ncbi.nlm.nih.gov/pubmed/22415236
http://dx.doi.org/10.1038/bjc.2012.70

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326670/
https://www.ncbi.nlm.nih.gov/pubmed/22415236
http://dx.doi.org/10.1038/bjc.2012.70

Ejemplares similares